Organogenesis Net Debt vs Total Stockholder Equity Analysis

ORGO Stock

USD 2.75 0.02 0.73%

Organogenesis Holdings financial indicator trend analysis is much more than just breaking down Organogenesis Holdings prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Organogenesis Holdings is a good investment. Please check the relationship between Organogenesis Holdings Net Debt and its Total Stockholder Equity accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.

Net Debt vs Total Stockholder Equity

Net Debt vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Organogenesis Holdings Net Debt account and Total Stockholder Equity. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Organogenesis Holdings' Net Debt and Total Stockholder Equity is 0.12. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Organogenesis Holdings, assuming nothing else is changed. The correlation between historical values of Organogenesis Holdings' Net Debt and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Organogenesis Holdings are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Net Debt i.e., Organogenesis Holdings' Net Debt and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.12

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most indicators from Organogenesis Holdings' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Organogenesis Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.At this time, Organogenesis Holdings' Tax Provision is very stable compared to the past year. As of the 2nd of June 2024, Sales General And Administrative To Revenue is likely to grow to 0.67, while Selling General Administrative is likely to drop about 146.1 M.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	114.2M	105.0M	123.4M	69.0M
Research Development	30.7M	39.8M	44.4M	46.6M

Cost Of Revenue Research Development

Organogenesis Holdings fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Good Will	Common Stock Total Equity	Retained Earnings Total Equity	Short Term Investments	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment
Total Assets		0.62	0.77	0.92	0.13	0.73	-0.34	0.84	0.82	0.56	0.16	0.86	0.85	0.26	0.41	0.43	0.75	0.68	0.79	0.8	0.67	0.82	0.73	0.64	0.26	0.7
Other Current Liab	0.62		0.6	0.51	-0.27	0.85	-0.13	0.65	0.61	0.22	-0.01	0.69	0.62	-0.18	0.61	0.36	0.55	0.88	0.61	0.6	0.8	0.64	0.74	0.26	-0.18	0.88
Total Current Liabilities	0.77	0.6		0.47	0.16	0.79	-0.72	0.88	0.93	0.53	-0.1	0.89	0.9	-0.34	0.4	0.38	0.8	0.75	0.98	0.99	0.54	0.95	0.87	0.64	-0.34	0.65
Total Stockholder Equity	0.92	0.51	0.47		0.09	0.54	-0.04	0.62	0.56	0.43	0.24	0.65	0.64	0.57	0.32	0.38	0.55	0.5	0.5	0.51	0.6	0.55	0.51	0.51	0.57	0.58
Other Liab	0.13	-0.27	0.16	0.09		-0.24	-0.58	0.16	0.06	-0.24	0.1	0.0	0.37	0.24	-0.49	0.08	0.26	-0.1	0.18	0.13	-0.41	0.06	0.12	0.64	0.24	-0.22
Net Tangible Assets	0.73	0.85	0.79	0.54	-0.24		-0.26	0.74	0.87	0.51	-0.1	0.87	0.69	-0.34	0.73	0.28	0.7	0.94	0.82	0.8	0.87	0.87	0.91	0.34	-0.34	0.89
Retained Earnings	-0.34	-0.13	-0.72	-0.04	-0.58	-0.26		-0.54	-0.53	-0.08	0.16	-0.38	-0.63	0.29	0.06	-0.09	-0.51	-0.34	-0.69	-0.7	0.13	-0.55	-0.49	-0.6	0.29	-0.1
Accounts Payable	0.84	0.65	0.88	0.62	0.16	0.74	-0.54		0.89	0.55	0.35	0.93	0.93	-0.14	0.23	0.61	0.92	0.73	0.9	0.91	0.65	0.9	0.76	0.72	-0.14	0.78
Cash	0.82	0.61	0.93	0.56	0.06	0.87	-0.53	0.89		0.65	0.01	0.96	0.83	-0.32	0.51	0.38	0.87	0.78	0.97	0.96	0.66	1.0	0.86	0.53	-0.32	0.73
Other Assets	0.56	0.22	0.53	0.43	-0.24	0.51	-0.08	0.55	0.65		0.09	0.69	0.42	-0.14	0.41	0.05	0.42	0.22	0.54	0.58	0.5	0.63	0.38	0.31	-0.14	0.37
Long Term Debt	0.16	-0.01	-0.1	0.24	0.1	-0.1	0.16	0.35	0.01	0.09		0.15	0.15	0.32	-0.54	0.65	0.41	-0.03	-0.06	-0.02	0.22	-0.02	-0.14	0.33	0.32	0.28
Net Receivables	0.86	0.69	0.89	0.65	0.0	0.87	-0.38	0.93	0.96	0.69	0.15		0.86	-0.22	0.45	0.52	0.88	0.78	0.92	0.91	0.79	0.96	0.86	0.59	-0.22	0.83
Good Will	0.85	0.62	0.9	0.64	0.37	0.69	-0.63	0.93	0.83	0.42	0.15	0.86		-0.05	0.24	0.5	0.83	0.72	0.89	0.89	0.55	0.85	0.8	0.84	-0.05	0.67
Common Stock Total Equity	0.26	-0.18	-0.34	0.57	0.24	-0.34	0.29	-0.14	-0.32	-0.14	0.32	-0.22	-0.05		-0.27	0.04	-0.18	-0.3	-0.34	-0.31	-0.14	-0.33	-0.32	0.15	1.0	-0.19
Retained Earnings Total Equity	0.41	0.61	0.4	0.32	-0.49	0.73	0.06	0.23	0.51	0.41	-0.54	0.45	0.24	-0.27		-0.31	0.09	0.57	0.42	0.42	0.55	0.5	0.5	-0.16	-0.27	0.43
Short Term Investments	0.43	0.36	0.38	0.38	0.08	0.28	-0.09	0.61	0.38	0.05	0.65	0.52	0.5	0.04	-0.31		0.71	0.4	0.39	0.36	0.48	0.39	0.34	0.42	0.04	0.59
Inventory	0.75	0.55	0.8	0.55	0.26	0.7	-0.51	0.92	0.87	0.42	0.41	0.88	0.83	-0.18	0.09	0.71		0.73	0.86	0.83	0.63	0.86	0.78	0.67	-0.18	0.78
Other Current Assets	0.68	0.88	0.75	0.5	-0.1	0.94	-0.34	0.73	0.78	0.22	-0.03	0.78	0.72	-0.3	0.57	0.4	0.73		0.78	0.75	0.81	0.79	0.91	0.4	-0.3	0.9
Other Stockholder Equity	0.79	0.61	0.98	0.5	0.18	0.82	-0.69	0.9	0.97	0.54	-0.06	0.92	0.89	-0.34	0.42	0.39	0.86	0.78		0.99	0.57	0.98	0.89	0.62	-0.34	0.69
Total Liab	0.8	0.6	0.99	0.51	0.13	0.8	-0.7	0.91	0.96	0.58	-0.02	0.91	0.89	-0.31	0.42	0.36	0.83	0.75	0.99		0.55	0.97	0.84	0.62	-0.31	0.66
Deferred Long Term Liab	0.67	0.8	0.54	0.6	-0.41	0.87	0.13	0.65	0.66	0.5	0.22	0.79	0.55	-0.14	0.55	0.48	0.63	0.81	0.57	0.55		0.66	0.73	0.3	-0.14	0.94
Total Current Assets	0.82	0.64	0.95	0.55	0.06	0.87	-0.55	0.9	1.0	0.63	-0.02	0.96	0.85	-0.33	0.5	0.39	0.86	0.79	0.98	0.97	0.66		0.88	0.55	-0.33	0.73
Short Term Debt	0.73	0.74	0.87	0.51	0.12	0.91	-0.49	0.76	0.86	0.38	-0.14	0.86	0.8	-0.32	0.5	0.34	0.78	0.91	0.89	0.84	0.73	0.88		0.58	-0.32	0.81
Intangible Assets	0.64	0.26	0.64	0.51	0.64	0.34	-0.6	0.72	0.53	0.31	0.33	0.59	0.84	0.15	-0.16	0.42	0.67	0.4	0.62	0.62	0.3	0.55	0.58		0.15	0.41
Common Stock	0.26	-0.18	-0.34	0.57	0.24	-0.34	0.29	-0.14	-0.32	-0.14	0.32	-0.22	-0.05	1.0	-0.27	0.04	-0.18	-0.3	-0.34	-0.31	-0.14	-0.33	-0.32	0.15		-0.19
Property Plant Equipment	0.7	0.88	0.65	0.58	-0.22	0.89	-0.1	0.78	0.73	0.37	0.28	0.83	0.67	-0.19	0.43	0.59	0.78	0.9	0.69	0.66	0.94	0.73	0.81	0.41	-0.19

Click cells to compare fundamentals

Organogenesis Holdings Account Relationship Matchups

Organogenesis Holdings fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	220.7M	294.5M	443.3M	449.4M	460.0M	292.5M
Other Current Liab	5.8M	2.1M	2.3M	26.4M	30.1M	31.6M
Total Current Liabilities	59.9M	68.2M	82.0M	75.0M	80.5M	48.2M
Total Stockholder Equity	55.6M	146.1M	242.0M	265.7M	278.7M	179.4M
Other Liab	7.7M	15.7M	1.6M	1.1M	1.3M	1.2M
Net Tangible Assets	9.2M	86.7M	187.6M	216.1M	248.5M	261.0M
Retained Earnings	(171.0M)	(153.1M)	(60.1M)	(45.3M)	(41.0M)	(43.0M)
Accounts Payable	28.4M	23.4M	29.3M	32.3M	30.7M	23.8M
Cash	60.2M	84.4M	113.9M	102.5M	104.3M	53.7M
Other Assets	1.6M	688K	33.5M	31.5M	1.0	0.95
Long Term Debt	83.1M	53.0M	70.8M	66.2M	60.7M	65.7M
Net Receivables	39.4M	56.8M	82.5M	89.5M	82.0M	52.7M
Common Stock Total Equity	293.0M	9K	10K	13K	11.7K	11.1K
Inventory	22.9M	27.8M	25.0M	24.8M	28.3M	20.8M
Other Current Assets	3.0M	4.9M	5.0M	5.1M	10.5M	11.0M
Other Stockholder Equity	226.6M	299.1M	302.2M	311.0M	319.6M	181.3M
Total Liab	165.1M	148.4M	201.2M	183.7M	181.4M	113.0M
Deferred Long Term Liab	318K	92K	370K	1.2M	1.4M	1.5M
Total Current Assets	125.6M	174.3M	227.0M	222.6M	225.0M	115.3M
Short Term Debt	3.1M	20.3M	14.6M	16.2M	19.7M	20.7M
Intangible Assets	20.8M	30.6M	25.7M	20.8M	15.9M	22.1M
Common Stock	293.0M	9K	10K	13K	11.7K	11.1K
Property Plant Equipment	47.2M	60.1M	79.2M	102.5M	117.8M	123.7M
Short Long Term Debt Total	100.6M	84.8M	132.3M	123.8M	119.4M	85.3M
Net Debt	40.4M	377K	18.4M	21.3M	15.0M	16.2M
Non Current Assets Total	95.1M	120.2M	216.3M	226.8M	235.0M	196.6M
Non Currrent Assets Other	884K	670K	1.5M	1.5M	6.0M	5.7M
Cash And Short Term Investments	60.2M	84.4M	113.9M	102.5M	104.3M	59.6M
Common Stock Shares Outstanding	92.8M	111.4M	133.7M	132.4M	132.7M	105.4M
Liabilities And Stockholders Equity	220.7M	294.5M	443.3M	449.4M	460.0M	324.6M
Non Current Liabilities Total	105.2M	80.2M	119.2M	108.7M	100.9M	71.7M
Capital Surpluse	226.6M	299.1M	302.2M	311.0M	357.6M	182.7M
Non Current Liabilities Other	6.6M	12.0M	48.5M	42.4M	1.2M	1.2M
Net Invested Capital	138.7M	215.8M	315.5M	336.4M	344.9M	273.1M
Net Working Capital	65.7M	106.1M	145.0M	147.6M	144.5M	95.9M
Property Plant And Equipment Net	47.2M	60.1M	128.3M	145.7M	156.3M	105.8M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Organogenesis Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organogenesis Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organogenesis Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organogenesis Holdings Stock:

How To Invest In Organogenesis

Details

Is Organogenesis Stock a good investment?

Details

What is Organogenesis Holdings' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.

Note that the Organogenesis Holdings information on this page should be used as a complementary analysis to other Organogenesis Holdings' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Complementary Tools for Organogenesis Stock analysis

When running Organogenesis Holdings' price analysis, check to measure Organogenesis Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Organogenesis Holdings is operating at the current time. Most of Organogenesis Holdings' value examination focuses on studying past and present price action to predict the probability of Organogenesis Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Organogenesis Holdings' price. Additionally, you may evaluate how the addition of Organogenesis Holdings to your portfolios can decrease your overall portfolio volatility.

	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Stocks Directory Find actively traded stocks across global markets
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Commodity Directory Find actively traded commodities issued by global exchanges

Is Organogenesis Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

11.307

Earnings Share

0.04

Revenue Per Share

3.313

Quarterly Revenue Growth

0.022

Return On Assets

0.0201

The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Organogenesis Net Debt vs Total Stockholder Equity Analysis

Net Debt vs Total Stockholder Equity

Net Debt vs Total Stockholder Equity Correlation Analysis

Correlation Coefficient

Net Debt

Total Stockholder Equity

Organogenesis Holdings fundamental ratios Correlations

Organogenesis Holdings Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Organogenesis Holdings fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Organogenesis Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 0.99	Total Current Liabilities
Total Liab	+ 0.99	Other Stockholder Equity
Other Stockholder Equity	+ 0.98	Total Current Liabilities
Total Current Assets	+ 0.98	Other Stockholder Equity

Retained Earnings	- 0.72	Total Current Liabilities
Total Liab	- 0.7	Retained Earnings
Other Stockholder Equity	- 0.69	Retained Earnings
Good Will	- 0.63	Retained Earnings
Intangible Assets	- 0.6	Retained Earnings
Retained Earnings	- 0.58	Other Liab